Skip to Main Content

Advertisement

Skip Nav Destination

David Miklos, MD, PhD: Ibrutinib in Chronic Graft-Versus-Host Disease

December 30, 2021

For patients who experience graft-versus-host disease after transplant and do not respond to corticosteroids, ibrutunib leads to a high, durable response rate, according to results from a phase II trial. Dr. Miklos discusses these results.

Advertisement

Connect with us:

CURRENT ISSUE
August 2022

Advertisement

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement